Government-Owned Inventions; Availability for Licensing, 46487-46489 [06-6872]
Download as PDF
<![CDATA[
46487
Federal Register / Vol. 71, No. 156 / Monday, August 14, 2006 / Notices
and organizations (e.g. cancer patients,
their families, the general public, health
providers, the media, voluntary groups,
scientific and medical organizations), it
is beneficial for NCI to pretest their
communications strategies, concepts,
and messages while they are under
development. The primary purpose of
this pretesting, or formative evaluation,
is to ensure that the messages,
communication materials, and
information services created by NCI
have the greatest capacity of being
received, understood, and accepted by
their target audiences. By utilizing
appropriate qualitative and quantitative
methodologies, NCI is able to (1)
understand characteristics of the
intended target audience—their
attitudes, beliefs, and behaviors—and
use this information in the development
of effective communication tools and
strategies; (2) produce or refine
messages that have the greatest potential
to influence target audience attitudes
and behavior in a positive manner; and
(3) expend limited program resource
dollars wisely and effectively.
Frequency of Response: On occasion.
Affected Public: Individuals or
households; Businesses or other for
profit; Not-for-profit institutions;
Federal Government; State, Local, or
Tribal Government. Type of
Respondents: Adult cancer patients;
members of the public; health care
professionals; organizational
representatives. The annual reporting
burden is as follows: Estimated Number
of Respondents: 13,780; Estimated
Number of Responses per Respondent:
1; Average Burden Hours Per Response:
.1458; and Estimated Total Annual
Burden Hours Requested: 2,010. The
annualized cost to respondents is
estimated at: $34,155. There are no
Capital Costs, Operating Costs, and/or
Maintenance Costs to report.
ESTIMATE HOURS OF BURDEN
No. of respondents
Type of respondents
Frequency of
response
Average time
per response
Annual hour
burden
Adults 18+ ........................................................................................................
13,780
1
.1458
2009.12
Total ..........................................................................................................
13,780
........................
........................
2009.12
Request For Comments: Written
comments and/or suggestions from the
public and affected agencies are invited
on one or more of the following points:
(1) Whether the proposed collection of
information is necessary for the proper
performance of the function of the
agency, including whether the
information will have practical utility;
(2) The accuracy of the agency’s
estimate of the burden of the proposed
collection of information, including the
validity of the methodology and
assumptions used; (3) Ways to enhance
the quality, utility, and clarity of the
information to be collected; and (4)
Ways to minimize the burden of the
collection of information on those who
are to respond, including the use of
appropriate automated, electronic,
mechanical, or other technological
collection techniques or other forms of
information technology.
To
request more information on the
proposed project or to obtain a copy of
the data collection plans and
instruments, contact Nina Goodman,
Senior Analyst, Operations Research
Office, OESI, NCI, NIH, 6116 Executive
Blvd., Suite 400, Rockville, MD 20892,
call non-toll-free number 301–435–7789
or e-mail your request, including your
address to: goodmann@mail.nih.gov.
Comments Due Date: Comments
regarding this information collection are
best assured of having their full effect if
received within 60 days of the date of
this publication.
jlentini on PROD1PC65 with NOTICES
FOR FURTHER INFORMATION CONTACT:
VerDate Aug<31>2005
17:58 Aug 11, 2006
Jkt 208001
Dated: August 2, 2006.
Rachelle Ragland-Greene,
NCI Project Clearance Liaison, National
Institutes of Health.
[FR Doc. E6–13190 Filed 8–11–06; 8:45 am]
BILLING CODE 4101–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions;
Availability for Licensing
National Institutes of Health,
Public Health Service, HHS.
AGENCY:
ACTION:
Notice.
SUMMARY: The inventions listed below
are owned by an agency of the U.S.
Government and are available for
licensing in the U.S. in accordance with
35 U.S.C. 207 to achieve expeditious
commercialization of results of
federally-funded research and
development. Foreign patent
applications are filed on selected
inventions to extend market coverage
for companies and may also be available
for licensing.
ADDRESSES: Licensing information and
copies of the U.S. patent applications
listed below may be obtained by writing
to the indicated licensing contact at the
Office of Technology Transfer, National
Institutes of Health, 6011 Executive
Boulevard, Suite 325, Rockville,
Maryland 20852–3804; telephone: 301/
496–7057; fax: 301/402–0220. A signed
Confidential Disclosure Agreement will
PO 00000
Frm 00042
Fmt 4703
Sfmt 4703
be required to receive copies of the
patent applications.
Real-Time Correction of Magnetic Field
Fluctuations in MIR
Description of Technology: Available
for licensing is a new MRI technique
that will markedly improve the
diagnostic potential of the rendered
images. This is a method for applying
real-time corrections to prevent image
distortions caused by field variations
that are due to the patient’s respiratory
cycle or instrument instability. These
field variations reduce the B0
homogeneity in a non-uniform and
spatially-dependent manner. They may
lead to a variety of image artifacts such
as ghosting and blurring. This method
provides a way of calculating the correct
electrical currents that must be applied
to a set of gradients and shims, smaller
magnets that are used to make fine-tune
adjustments to the magnetic field in a
spatially-dependent manner. As the MRI
subject breathes, changes in the B0 field
occur. During a brief training session,
the amplitude of these changes as a
function of chest motion is recorded in
a phase map. Similarly, changes in B0 as
a function of chest motion is recorded
in a phase map. Similarly, changes in B0
as a function of current intensity is
available from calibration data
containing B0 as a function of coil
current. As the subject undergoes a
scan, compensatory currents are applied
to the x, y, or z axis of the gradients and
the shims coils in order to correct for
the effect of respiration on the B0
homogeneity. The shim values can be
updated every 10 to 80 milliseconds
E:\FR\FM\14AUN1.SGM
14AUN1
46488
Federal Register / Vol. 71, No. 156 / Monday, August 14, 2006 / Notices
jlentini on PROD1PC65 with NOTICES
during an experiment. This method
results in a substantial decrease in
artifacts that can obscure the overall
image quality. It can be used for
virtually all types of scans and MRI
instruments.
Applications: (1) Real-time correction
of magnetic fluctuations in MRI
experiments; (2) Improved MRI image
precision.
Market: MRI manufacturers, hospitals,
medical research centers, and
universities.
Development Status: The technology
is ready to be used and requires no
further testing or development.
Inventors: Jozef H. Duyn (NINDS),
Peter van Gelderen (NINDS), et al.
Related Publication: P van Gelderen,
JA de Zwart, P Starewicz, RS Hinks, JH
Duyn. Real time shimming for
compensation of respiration induced
field changes. Proceedings ISMRM
2006, page 752.
Patent Status: U.S. Provisional
Application No. 60/781,246 filed 10 Mar
2006 (HHS Reference No. E–085–2006/
0–US–01).
Licensing Status: Available for nonexclusive or exclusive licensing.
Licensing Contact: Chekesha
Clingman, Ph.D.; 301/435–5018;
clingmac@mail.nih.gov
Collaborative Research Opportunity:
The National Institute of Neurological
Disorders and Stroke is seeking
statements of capability or interest from
parties interested in collaorative
research to further develop, evaluate, or
commercialize this technology. Please
contact Martha Lubet at 301/435–3120
or lubetm@mail.nih.gov for more
information.
Microdialysis Probe for
Musculoskeletal Tissue Stimulation
and Biochemical Analysis
Description of Technology: Available
for licensing and commercial
development is a microdialysis probe
made from a small-bore (32 gauge)
needle containing both a fluid delivery
and recovery tube within the bore. A
molecular exchange membrane is
positioned about 200 microns from the
tip. Fluid flows across the membrane
removing diffused molecules to a
collection device. The rounded tip of
the needle is designed to cause minimal
tissue damage while allowing
investigations to be performed on local
tissue fluids. Additionally, this device
allows simultaneous delivery of small
concentrations of drug to the area
immediately surrounding the device tip.
The device is actively used to study the
pathophysiology of myofascial trigger
points (MTrPs), a very common physical
finding and cause of musculoskeletal
VerDate Aug<31>2005
17:58 Aug 11, 2006
Jkt 208001
pain and disability. The device allows
for safe in situ exploration of myofascial
pain biochemistry with minimal system
perturbation.
Applications: (1) Muscular
stimulation; (2) Musculoskeletal pain;
(3) Myofascial Trigger Points.
Market: (1) Drug Discovery; (2) Pain
management.
Inventors: Jay Shah (NIHCC), Terence
Martyn Phillips (ORS), Jerome V. Danoff
(NIHCC), Lynn Gerber (NIHCC).
Patent Status: U.S. Provisional
Application No. 60/795,176 filed 27 Apr
2006 (HHS Reference No. E–024–2006/
0–US–01).
Licensing Status: Available for nonexclusive or exclusive licensing.
Licensing Contact: Michael A.
Shmilovich, Esq.; 301/435–5019;
shmilovm@mail.nih.gov
tests for a large number of pathogens, as
well as various microorganisms and cell
types. It can also be used to isolate
microorganisms from aqueous
suspensions as well as spores, including
airborne ones.
Inventors: Magdi M. Mossoba and
Sufian Al-Khaldi (FDA).
Patent Status: U.S. Patent Application
No. 11/343,561 filed 30 Jan 2006,
entitled ‘‘Hydrophilic IR transparent
membrane, spectroscopic sample holder
comprising same and methods of using
same’’ (HHS Reference No. E–174–2005/
0–US–01).
Licensing Status: Available for nonexclusive or exclusive licensing.
Licensing Contract: Cristina
Thalhammer-Reyero, Ph.D., M.B.A.;
301/435–4507; thalhamc@mail.nih.gov.
Novel Infrared (IR)-Transparent
Hydrophilic Membrane That Can be
Used for Filtration, Printing or
Microarrays, and Cultivation of
Bacteria and Other Microorganisms for
Reagent-Free IR Spectroscopic
Identification
Description of Technology: Available
for licensing and commercial
development is a novel, disposable
infrared (IR)-transparent, microporous,
plasma treated polyethylene
hydrophilic membrane, as well as
methods for making and using this
membrane to identify bacterial and
other micoorganism impurities in food
using IR spectroscopy. Further
applications include: filtering dilute
aqueous bacterial suspensions, and
growing bacterial colonies when the PE
membrane is placed over an agar
medium and incubated. The patent also
describes a novel high-throughout
technique, as an alternative to manual
filtration, where the PE membrane is
used for microarray printing of intact
microorganisms in pre-enriched
medium on the treated PE substrate.
Furthermore, the invention relates to a
method of detecting mixtures of foodborne pathogens E. sakazakii and K.
pneumonia, by using the treated PE
membranes. Because this unique
membrane is transparent to infrared
light, isolated microcolonies of bacterial
cells grown on this PE substrate can be
fingerprinted directly by IR
microspectroscopy, followed by
multivariate analysis for the
identification of the pathogens. The
method can be applied to other cell
types as well.
This novel membrane and its
applications offer an advantage over
existing tests in that it can be used to
rapidly identify presumptive pathogen
colonies, and can be used in screening
Porcine Rotavirus Reassortant
Compositions
PO 00000
Frm 00043
Fmt 4703
Sfmt 4703
Description of Technology:
Rotaviruses are the predominant cause
of severe diarrhea and dehydration in
infants and young children and are
associated with approximately 600,000
deaths each year worldwide. Although
death from rotavirus infection occurs
more frequently in developing countries
an estimated 55,000–70,000
hospitalizations and 20 to 60 deaths
occur yearly in the United States. Thus,
accelerating the availability of a safe and
effective rotavirus vaccine represents a
global public health priority.
Available for licensing and
commercial development are newly
developed human rotavirus-porcine
rotavirus reassortant vaccine
compositions and methodology for their
use in humans. This technology
provides immunogenic compositions of
reassortant human-porcine rotaviruses
with VP7 specificity of the most
clinically prevalent serotypes of human
rotavirus found in various regions of the
world. These compositions, which need
clinical evaluation, should be able to
induce an immunogenic response
specific to human rotavirus serotypes
that is protective against symptoms of
serious rotaviral disease, such as severe
diarrhea and dehydration. Porcine
rotaviruses are genetically more closely
related to human rotavirus strains
compared to rhesus and bovine
rotaviruses.
Applications: (1) Resistance to
developing severe human rotaviral
disease; (2) Safe and effective global
infant vaccinations.
Market: (1) Rotaviral infections result
in approximately 600,000 deaths yearly;
(2) Anti-rotavirus technology has a
projected market of more than 1.0
billion dollars by 2010.
E:\FR\FM\14AUN1.SGM
14AUN1
Federal Register / Vol. 71, No. 156 / Monday, August 14, 2006 / Notices
jlentini on PROD1PC65 with NOTICES
Development Status: Preclinical data
is available at this time.
Inventors: Yasutaka Hoshino and
Albert Z. Kapikian (NIAID).
Related Publications:
1. Y Hoshino, RW Jones, J Ross, AZ
Kapikian. Porcine rotavirus strain
Gottfried-based human rotavirus
candidate vaccines: construction and
characterization. Vaccine 2005 May
31;23(29):3791–3799.
2. M Gorziglia, K Nishikawa, Y
Hoshino, K Taniguchi. Similarity of the
outer capsid protein VP4 of the
Gottfried strain of porcine rotavirus to
that asymptomatic human rotavirus
strains. J Virology, 1990 Jan;64(1):414–
418.
Patent Status: U.S. Provisional
Application No. 60/698,572 filed 11 Jul
2005 (HHS Reference No. E–056–2005/
0–US–01)
Licensing Status: Available for nonexclusive or exclusive licensing.
Licensing Contact: Chekesha
Clingman, Ph.D.; 301/435–5018;
clingmac@mail.nih.gov.
Adoptive T-Cell Transfer After
Lymphodepletion Promotes Tumor
Regression
Description of Technology: Available
for licensing is a method of adoptive
cell transfer (ACT) immunotherapy.
Since its first description, ACT is now
being developed for the supportive
treatment of a variety of infectious
diseases and cancer.
Current ACT methods to treat cancer
are based on the ex vivo selection of
lymphocytes with high avidity for
recognition of tumor antigens, and their
activation and numerical expansion
before re-infusion to the autologous
tumor-bearing host. The current
invention improves ACT by including a
pre-treatment regimen to ensure
permissive conditions in the host for in
vivo proliferation of the transferred
cells. Specifically, the immune system
is suppressed by pre-treatment with
lymphodepleting chemotherapy. Two
separate clinical trials have
demonstrated that using this approach,
ACT can induce lasting tumor
shrinkage.
Lymphodepleting chemotherapy
followed by ACT resulted in tumor
shrinkage of at least 50 percent in 6 out
of 13 treated patients suffering from
refractory melanoma. Several patients
remained cancer free for more than a
year after treatment. The usefulness of
combined ACT and lymphodepleting
therapy for cancer treatment was
confirmed when this study was
extended to include 35 melanoma
patients. Eighteen of the 35 patients
(51%) responded to the treatment,
VerDate Aug<31>2005
17:58 Aug 11, 2006
Jkt 208001
including 3 patients who experienced
ongoing complete disappearance of
cancer and 15 patients had tumor
shrinkage of at least 50 percent with a
mean duration of almost a year after
treatment. In a recent clinical trial that
is not yet published, using a modified
protocol to treat 23 patients, a similar
response rate (56%) was seen.
This approach to ACT offers a
potentially significant improvement in
the treatment of many types of cancer.
In addition, this method might be
applicable in treating other diseases
such as AIDS, immunodeficiency, or
other autoimmunity for which immune
effector cells can impact the clinical
outcome.
Inventors: Mark E. Dudley, Steven A.
Rosenberg, John R. Wunderlich (NC).
Publications:
1. Dudley ME, et al. ‘‘Adoptive cell
transfer therapy following nonmyeloablative but lymphodepleting
chemotherapy for the treatment of
patients with refractory metastatic
melanoma.’’ J Clin Oncol. 2005 Apr
1;23(10):2346–2357.
2. Dudley ME, et al. ‘‘Cancer
regression and autoimmunity in patients
after clonal repopulation with antitumor
lymphocytes.’’ Science. 2002 Oct
25;298(5594):850–854.
Patent Status: U.S. Provisional
Application No. 60/408,681 filed 06 Sep
2002 (HHS Reference No. E–275–2002/
0–US–01); PCT Application No. PC/
US03/27873 filed 05 Sep 2003, which
published as WO 2004/021995 on 18
Mar 2004 (HHS Reference No. E–275–
2002/1–PCT–01); U.S. Patent
Application No. 10/526,697 filed 05
May 2005 (HHS Reference No. E–275–
2002/1–US–02).
Licensing Status: Available for
exclusive and non-exclusive licensing.
Licensing Contact: Michelle A.
Booden, Ph.D.; 301/451–7337;
boodenm@mail.nih.gov.
Collaborative Research Opportunity:
The NCI Surgery Branch is seeking
statements of capability or interest from
parties interested in collaborative
research to further develop, evaluate, or
commercialize ACT therapy. Please
contact Steven A. Rosenberg, M.D.,
Ph.D. at 301/496–4164 for more
information.
Dated: July 28, 2006.
Steven M. Ferguson,
Director, Division of Technology Development
and Transfer, Office of Technology Transfer,
National Institutes of Health.
[FR Doc. 06–6872 Filed 8–11–06 8:45 am]
BILLING CODE 4140–01–M
PO 00000
Frm 00044
Fmt 4703
Sfmt 4703
46489
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions;
Availability for Licensing
National Institutes of Health,
Public Health Service, HHS.
ACTION: Notice.
AGENCY:
SUMMARY: The inventions listed below
are owned by an agency of the U.S.
Government and are available for
licensing in the U.S. in accordance with
35 U.S.C. 207 to achieve expeditious
commercialization of results of
federally-funded research and
development. Foreign patent
applications are filed on selected
inventions to extend market coverage
for companies and may also be available
for licensing.
ADDRESSES: Licensing information and
copies of the U.S. patent applications
listed below may be obtained by writing
to the indicated licensing contact at the
Office of Technology Transfer, National
Institutes of Health, 6011 Executive
Boulevard, Suite 325, Rockville,
Maryland 20852–3804; telephone: 301/
496–7057; fax: 301/402–0220. A signed
Confidential Disclosure Agreement will
be required to receive copies of the
patent applications.
Hollow Waveguide Laser Delivery
System for Digital Particle Image
Velocity
Description of Technology
Available for licensing and
commercial development is an allhollow-waveguide laser delivery system
used for effective digital particle image
velocimetry (DPIV) illumination. The
System incorporates two key optical
hollow waveguide components: An
uncoated funnel-shaped hollow glass
taper for a direct laser-to-taper coupling
and a flexible hollow core waveguide
for precise high-peak-power laser
delivery. The principle of operation of
the uncoated hollow taper is based on
grazing-incidence effect. The optical
taper is used for direct lens-free
launching of laser radiation including
from powerful lasers into fibers and
waveguides. Because of the mutual
action of the direct parallel laser
excitation, the mode coupling process
and mode filtering effect, the hollow
taper serves as a mode converter that
transforms the highly multimode profile
of the input laser emission into a highquality Gaussian-shaped profile at the
taper output. Moreover, because of the
lower power density of the output laser
beam and its high causality profile, the
E:\FR\FM\14AUN1.SGM
14AUN1
]]>Agencies
[Federal Register Volume 71, Number 156 (Monday, August 14, 2006)]
[Notices]
[Pages 46487-46489]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 06-6872]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions; Availability for Licensing
AGENCY: National Institutes of Health, Public Health Service, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The inventions listed below are owned by an agency of the U.S.
Government and are available for licensing in the U.S. in accordance
with 35 U.S.C. 207 to achieve expeditious commercialization of results
of federally-funded research and development. Foreign patent
applications are filed on selected inventions to extend market coverage
for companies and may also be available for licensing.
ADDRESSES: Licensing information and copies of the U.S. patent
applications listed below may be obtained by writing to the indicated
licensing contact at the Office of Technology Transfer, National
Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville,
Maryland 20852-3804; telephone: 301/496-7057; fax: 301/402-0220. A
signed Confidential Disclosure Agreement will be required to receive
copies of the patent applications.
Real-Time Correction of Magnetic Field Fluctuations in MIR
Description of Technology: Available for licensing is a new MRI
technique that will markedly improve the diagnostic potential of the
rendered images. This is a method for applying real-time corrections to
prevent image distortions caused by field variations that are due to
the patient's respiratory cycle or instrument instability. These field
variations reduce the B0 homogeneity in a non-uniform and
spatially-dependent manner. They may lead to a variety of image
artifacts such as ghosting and blurring. This method provides a way of
calculating the correct electrical currents that must be applied to a
set of gradients and shims, smaller magnets that are used to make fine-
tune adjustments to the magnetic field in a spatially-dependent manner.
As the MRI subject breathes, changes in the B0 field occur.
During a brief training session, the amplitude of these changes as a
function of chest motion is recorded in a phase map. Similarly, changes
in B0 as a function of chest motion is recorded in a phase
map. Similarly, changes in B0 as a function of current
intensity is available from calibration data containing B0
as a function of coil current. As the subject undergoes a scan,
compensatory currents are applied to the x, y, or z axis of the
gradients and the shims coils in order to correct for the effect of
respiration on the B0 homogeneity. The shim values can be
updated every 10 to 80 milliseconds
[[Page 46488]]
during an experiment. This method results in a substantial decrease in
artifacts that can obscure the overall image quality. It can be used
for virtually all types of scans and MRI instruments.
Applications: (1) Real-time correction of magnetic fluctuations in
MRI experiments; (2) Improved MRI image precision.
Market: MRI manufacturers, hospitals, medical research centers, and
universities.
Development Status: The technology is ready to be used and requires
no further testing or development.
Inventors: Jozef H. Duyn (NINDS), Peter van Gelderen (NINDS), et
al.
Related Publication: P van Gelderen, JA de Zwart, P Starewicz, RS
Hinks, JH Duyn. Real time shimming for compensation of respiration
induced field changes. Proceedings ISMRM 2006, page 752.
Patent Status: U.S. Provisional Application No. 60/781,246 filed 10
Mar 2006 (HHS Reference No. E-085-2006/0-US-01).
Licensing Status: Available for non-exclusive or exclusive
licensing.
Licensing Contact: Chekesha Clingman, Ph.D.; 301/435-5018;
clingmac@mail.nih.gov
Collaborative Research Opportunity: The National Institute of
Neurological Disorders and Stroke is seeking statements of capability
or interest from parties interested in collaorative research to further
develop, evaluate, or commercialize this technology. Please contact
Martha Lubet at 301/435-3120 or lubetm@mail.nih.gov for more
information.
Microdialysis Probe for Musculoskeletal Tissue Stimulation and
Biochemical Analysis
Description of Technology: Available for licensing and commercial
development is a microdialysis probe made from a small-bore (32 gauge)
needle containing both a fluid delivery and recovery tube within the
bore. A molecular exchange membrane is positioned about 200 microns
from the tip. Fluid flows across the membrane removing diffused
molecules to a collection device. The rounded tip of the needle is
designed to cause minimal tissue damage while allowing investigations
to be performed on local tissue fluids. Additionally, this device
allows simultaneous delivery of small concentrations of drug to the
area immediately surrounding the device tip. The device is actively
used to study the pathophysiology of myofascial trigger points (MTrPs),
a very common physical finding and cause of musculoskeletal pain and
disability. The device allows for safe in situ exploration of
myofascial pain biochemistry with minimal system perturbation.
Applications: (1) Muscular stimulation; (2) Musculoskeletal pain;
(3) Myofascial Trigger Points.
Market: (1) Drug Discovery; (2) Pain management.
Inventors: Jay Shah (NIHCC), Terence Martyn Phillips (ORS), Jerome
V. Danoff (NIHCC), Lynn Gerber (NIHCC).
Patent Status: U.S. Provisional Application No. 60/795,176 filed 27
Apr 2006 (HHS Reference No. E-024-2006/0-US-01).
Licensing Status: Available for non-exclusive or exclusive
licensing.
Licensing Contact: Michael A. Shmilovich, Esq.; 301/435-5019;
shmilovm@mail.nih.gov
Novel Infrared (IR)-Transparent Hydrophilic Membrane That Can be Used
for Filtration, Printing or Microarrays, and Cultivation of Bacteria
and Other Microorganisms for Reagent-Free IR Spectroscopic
Identification
Description of Technology: Available for licensing and commercial
development is a novel, disposable infrared (IR)-transparent,
microporous, plasma treated polyethylene hydrophilic membrane, as well
as methods for making and using this membrane to identify bacterial and
other micoorganism impurities in food using IR spectroscopy. Further
applications include: filtering dilute aqueous bacterial suspensions,
and growing bacterial colonies when the PE membrane is placed over an
agar medium and incubated. The patent also describes a novel high-
throughout technique, as an alternative to manual filtration, where the
PE membrane is used for microarray printing of intact microorganisms in
pre-enriched medium on the treated PE substrate. Furthermore, the
invention relates to a method of detecting mixtures of food-borne
pathogens E. sakazakii and K. pneumonia, by using the treated PE
membranes. Because this unique membrane is transparent to infrared
light, isolated microcolonies of bacterial cells grown on this PE
substrate can be fingerprinted directly by IR microspectroscopy,
followed by multivariate analysis for the identification of the
pathogens. The method can be applied to other cell types as well.
This novel membrane and its applications offer an advantage over
existing tests in that it can be used to rapidly identify presumptive
pathogen colonies, and can be used in screening tests for a large
number of pathogens, as well as various microorganisms and cell types.
It can also be used to isolate microorganisms from aqueous suspensions
as well as spores, including airborne ones.
Inventors: Magdi M. Mossoba and Sufian Al-Khaldi (FDA).
Patent Status: U.S. Patent Application No. 11/343,561 filed 30 Jan
2006, entitled ``Hydrophilic IR transparent membrane, spectroscopic
sample holder comprising same and methods of using same'' (HHS
Reference No. E-174-2005/0-US-01).
Licensing Status: Available for non-exclusive or exclusive
licensing.
Licensing Contract: Cristina Thalhammer-Reyero, Ph.D., M.B.A.; 301/
435-4507; thalhamc@mail.nih.gov.
Porcine Rotavirus Reassortant Compositions
Description of Technology: Rotaviruses are the predominant cause of
severe diarrhea and dehydration in infants and young children and are
associated with approximately 600,000 deaths each year worldwide.
Although death from rotavirus infection occurs more frequently in
developing countries an estimated 55,000-70,000 hospitalizations and 20
to 60 deaths occur yearly in the United States. Thus, accelerating the
availability of a safe and effective rotavirus vaccine represents a
global public health priority.
Available for licensing and commercial development are newly
developed human rotavirus-porcine rotavirus reassortant vaccine
compositions and methodology for their use in humans. This technology
provides immunogenic compositions of reassortant human-porcine
rotaviruses with VP7 specificity of the most clinically prevalent
serotypes of human rotavirus found in various regions of the world.
These compositions, which need clinical evaluation, should be able to
induce an immunogenic response specific to human rotavirus serotypes
that is protective against symptoms of serious rotaviral disease, such
as severe diarrhea and dehydration. Porcine rotaviruses are genetically
more closely related to human rotavirus strains compared to rhesus and
bovine rotaviruses.
Applications: (1) Resistance to developing severe human rotaviral
disease; (2) Safe and effective global infant vaccinations.
Market: (1) Rotaviral infections result in approximately 600,000
deaths yearly; (2) Anti-rotavirus technology has a projected market of
more than 1.0 billion dollars by 2010.
[[Page 46489]]
Development Status: Preclinical data is available at this time.
Inventors: Yasutaka Hoshino and Albert Z. Kapikian (NIAID).
Related Publications:
1. Y Hoshino, RW Jones, J Ross, AZ Kapikian. Porcine rotavirus
strain Gottfried-based human rotavirus candidate vaccines: construction
and characterization. Vaccine 2005 May 31;23(29):3791-3799.
2. M Gorziglia, K Nishikawa, Y Hoshino, K Taniguchi. Similarity of
the outer capsid protein VP4 of the Gottfried strain of porcine
rotavirus to that asymptomatic human rotavirus strains. J Virology,
1990 Jan;64(1):414-418.
Patent Status: U.S. Provisional Application No. 60/698,572 filed 11
Jul 2005 (HHS Reference No. E-056-2005/0-US-01)
Licensing Status: Available for non-exclusive or exclusive
licensing.
Licensing Contact: Chekesha Clingman, Ph.D.; 301/435-5018;
clingmac@mail.nih.gov.
Adoptive T-Cell Transfer After Lymphodepletion Promotes Tumor
Regression
Description of Technology: Available for licensing is a method of
adoptive cell transfer (ACT) immunotherapy. Since its first
description, ACT is now being developed for the supportive treatment of
a variety of infectious diseases and cancer.
Current ACT methods to treat cancer are based on the ex vivo
selection of lymphocytes with high avidity for recognition of tumor
antigens, and their activation and numerical expansion before re-
infusion to the autologous tumor-bearing host. The current invention
improves ACT by including a pre-treatment regimen to ensure permissive
conditions in the host for in vivo proliferation of the transferred
cells. Specifically, the immune system is suppressed by pre-treatment
with lymphodepleting chemotherapy. Two separate clinical trials have
demonstrated that using this approach, ACT can induce lasting tumor
shrinkage.
Lymphodepleting chemotherapy followed by ACT resulted in tumor
shrinkage of at least 50 percent in 6 out of 13 treated patients
suffering from refractory melanoma. Several patients remained cancer
free for more than a year after treatment. The usefulness of combined
ACT and lymphodepleting therapy for cancer treatment was confirmed when
this study was extended to include 35 melanoma patients. Eighteen of
the 35 patients (51%) responded to the treatment, including 3 patients
who experienced ongoing complete disappearance of cancer and 15
patients had tumor shrinkage of at least 50 percent with a mean
duration of almost a year after treatment. In a recent clinical trial
that is not yet published, using a modified protocol to treat 23
patients, a similar response rate (56%) was seen.
This approach to ACT offers a potentially significant improvement
in the treatment of many types of cancer. In addition, this method
might be applicable in treating other diseases such as AIDS,
immunodeficiency, or other autoimmunity for which immune effector cells
can impact the clinical outcome.
Inventors: Mark E. Dudley, Steven A. Rosenberg, John R. Wunderlich
(NC).
Publications:
1. Dudley ME, et al. ``Adoptive cell transfer therapy following
non-myeloablative but lymphodepleting chemotherapy for the treatment of
patients with refractory metastatic melanoma.'' J Clin Oncol. 2005 Apr
1;23(10):2346-2357.
2. Dudley ME, et al. ``Cancer regression and autoimmunity in
patients after clonal repopulation with antitumor lymphocytes.''
Science. 2002 Oct 25;298(5594):850-854.
Patent Status: U.S. Provisional Application No. 60/408,681 filed 06
Sep 2002 (HHS Reference No. E-275-2002/0-US-01); PCT Application No.
PC/US03/27873 filed 05 Sep 2003, which published as WO 2004/021995 on
18 Mar 2004 (HHS Reference No. E-275-2002/1-PCT-01); U.S. Patent
Application No. 10/526,697 filed 05 May 2005 (HHS Reference No. E-275-
2002/1-US-02).
Licensing Status: Available for exclusive and non-exclusive
licensing.
Licensing Contact: Michelle A. Booden, Ph.D.; 301/451-7337;
boodenm@mail.nih.gov.
Collaborative Research Opportunity: The NCI Surgery Branch is
seeking statements of capability or interest from parties interested in
collaborative research to further develop, evaluate, or commercialize
ACT therapy. Please contact Steven A. Rosenberg, M.D., Ph.D. at 301/
496-4164 for more information.
Dated: July 28, 2006.
Steven M. Ferguson,
Director, Division of Technology Development and Transfer, Office of
Technology Transfer, National Institutes of Health.
[FR Doc. 06-6872 Filed 8-11-06 8:45 am]
BILLING CODE 4140-01-M
